ClinicalTrials.gg
RecruitingNCT06538311Updated May 6, 2026

Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease

An Early Phase 1 interventional study of Active rTMS and Sham rTMS in Alzheimer Disease, Mild Cognitive Impairment and Logopenic Progressive Aphasia, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 40 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Massachusetts General Hospital · Early Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled May 2023, registered Aug 2024).
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
40 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Alzheimer Disease by Massachusetts General Hospital — 9 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Massachusetts General Hospital.

Planned enrollment
10th of 25
30 · median 20
Started
2023
with 2 others
Phase 1
2 of 29
1 open now
Registered
26th of 29
by date

Among the 29 studies in Alzheimer Disease by Massachusetts General Hospital, this one is the 10th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 1, and was the 26th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 29 studies in Alzheimer Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 40 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Alzheimer Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

In this research study we want to learn more about the effects of non-invasive brain stimulation on memory and brain-network function in cognitively unimpaired older adults and in patients with amnestic mild cognitive impairment (aMCI).

This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls memory. Changes resulting from this stimulation will be measured with behavioral tests of memory and general cognition, as well as by taking images of your brain with Magnetic Resonance Imaging (MRI).

Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.

03

Conditions studied

  • Alzheimer Disease
  • Mild Cognitive Impairment
  • Logopenic Progressive Aphasia
  • Amnestic Symptoms

Keywords

  • Transcranial Magnetic Stimulation
04

Who can participate

Ages eligible
40 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Between the ages of 40-99
  2. Native English speakers
  3. Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points
  4. Patients with PPA will be asked to bring a study partner to all visits
  5. Patients with very mild or mild PPA, patients with amnestic mild cognitive impairment and cognitively unimpaired participants with preclinical AD will be included.

Exclusion criteria

Exclusion Criteria:

  1. History of head trauma involving loss of consciousness or alteration in consciousness
  2. Another major neurologic or psychiatric condition
  3. Known presence of a structural brain lesion (e.g. tumor, cortical infarct)
  4. Any to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
  5. Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
  6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.
  7. Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging
  8. History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).
  9. Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.
  10. Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.
  11. Subjects actively on anti-amyloid treatments. This is because they are at risk for bleeding due to amyloid-related imaging abnormalities (ARIA) that could provoke seizures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    AD, aMCI, lvPPA patients, and preclinical AD

    All participants will receive the same study interventions in a within-subject crossover design.

    Device: Active rTMS · Device: Sham rTMS

Interventions

  • DeviceActive rTMS

    All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).

  • DeviceSham rTMS

    All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).

06

What researchers measure

Primary outcomes

  1. Changes in Memory

    This will include observed changes in memory as a result of the stimulation through neuropsychological testing.

    Time frame: Baseline and post-treatment Day 11

  2. Changes in Brain Network Connectivity

    This will include observed changes in resting-state functional connectivity as a result of the stimulation.

    Time frame: Baseline and post-treatment Day 11

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang JX, Rogers LM, Gross EZ, Ryals AJ, Dokucu ME, Brandstatt KL, Hermiller MS, Voss JL. Targeted enhancement of cortical-hippocampal brain networks and associative memory. Science. 2014 Aug 29;345(6200):1054-7. doi: 10.1126/science.1252900. PubMed 25170153 ↗
  • Damoiseaux JS, Prater KE, Miller BL, Greicius MD. Functional connectivity tracks clinical deterioration in Alzheimer's disease. Neurobiol Aging. 2012 Apr;33(4):828.e19-30. doi: 10.1016/j.neurobiolaging.2011.06.024. Epub 2011 Aug 16. PubMed 21840627 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Mar 2027, 46 months after the start.

Of 73 non-industry phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 46 months is close to that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 5, 2024
StartActual
May 1, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06538311
Responsible party
Alexandra Touroutoglou (Assistant Professor of Neurology, Harvard Medical School (HMS and HSDM)) — Principal investigator
First posted
Aug 5, 2024
Start date
May 1, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 6, 2026

Study contacts

Alexandra Touroutoglou, PhD
Contact
atouroutoglou@mgh.harvard.edu
6176436348
Jordan Walter, BA
Contact
jwalter2@mgh.harvard.edu
6177266207

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion